Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.
about
Advances in Diagnosis and Treatments for Immune ThrombocytopeniaPhenotyping bleedingImmune thrombocytopeniaAdvances in ITP--therapy and quality of life--a patient surveyTherapeutic implications of T-cell clonopathy of unknown significance in chronic immune thrombocytopenic purpura.Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.Repeated courses of rituximab in chronic ITP: Three different regimens.Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopeniaCosts of managing severe immune thrombocytopenia in adults: a retrospective analysis.Durability and factors associated with long term response after splenectomy for primary immune thrombocytopenia (ITP) and outcome of relapsed or refractory patients.Long-term management of chronic immune thrombocytopenic purpura in adults.Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.Current treatment options for primary immune thrombocytopenia.Eltrombopag for the treatment of immune thrombocytopenia.Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patientsTargeting B cells in severe thrombotic thrombocytopenic purpura--a road to cure?[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].Sequence of treatments for adults with primary immune thrombocytopenia.Patient-reported treatment burden of chronic immune thrombocytopenia therapies.Risk and prognosis of adult primary immune thrombocytopenia.Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura.Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice.B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile.Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in IrelandRituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.Romiplostim as early treatment for refractory primary immune thrombocytopenia.Contemporary treatment of immune thrombocytopenia.Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy.Management of thrombocytopenia.A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.
P2860
Q26738630-3F3EEAD7-92D4-446D-8A02-13BD0999870DQ26830732-42FF045E-8BC5-4BEE-BAA6-7D66509927A3Q26830918-33700D69-7EC7-4758-B386-6D481D3AA30BQ28742871-C3234FA0-637F-44E8-97F6-9658D45EBD8AQ33383399-3D2C9BE0-05BE-4AE6-AB51-D082DD1DC6BCQ33385389-2511F427-4507-41AB-9CB4-28F84F681384Q33386117-5F0CE35B-5E5F-4C09-ACFE-BC29C0EE3C56Q33389001-C62282B5-06B1-4D5A-9C8B-E7037E027A78Q33392179-35B45FD9-589E-4300-85A3-CF1012063B27Q33392406-9530C40F-07A6-432C-B6BF-89F642A6B22BQ33392610-E2DE0C97-BE85-45F9-B4FB-9E7A5A6832A3Q33392868-D42C2F37-1843-42C7-8BD6-F5DC2665F8ECQ33394149-4E0ED894-D491-4B8C-BC4A-5440CA736068Q33395776-938EA24B-F27C-42E2-A9BB-2CA642A17657Q33395961-8887D2CA-135F-4049-92CD-9AE720712400Q33396902-79A96C08-1FBC-4670-987E-E90CF00665F1Q33397525-94BD686D-AF3A-48B9-B7FC-88CAD7B913C9Q33398799-2B11286E-2649-4B58-BF2C-67815EEA7B79Q33400018-6879C8E7-965D-4513-8DFC-89A7C3471155Q33400072-571EF3EB-1DFD-4835-BF7F-6F6C622EB1C8Q33400348-598FACBF-EA68-4AE4-879C-014C7E5543CBQ33400566-861675B8-F58B-4D88-9C5A-2BBD7A75A67CQ33401100-30E234C1-D922-4A84-8AAE-5BAAE42ADFAAQ33401321-52FAC82E-EB4F-4F47-888C-00518B7833AFQ33401898-E10CB544-3AD0-4C79-9D95-B66AE823A73BQ33402069-4705A302-36C7-4E5B-A40E-CF510AD849CDQ33402591-2A0CCE44-490B-4954-A452-872EE6EA2008Q33404032-6093729E-7975-4745-B6E6-51C2BA1100ECQ33404838-4BCFA243-7E95-47EE-9763-8D5B2823CB01Q33406838-4EA4D4BA-1172-42CB-9F61-CAAB519D9E5DQ33408621-490FABCE-E15B-4D23-9625-7113BCE32077Q33408915-FCE35B42-BE26-4C69-B3E2-08090A8522BCQ33409109-AF3C2DD1-DA42-467A-BB33-39A7CB566F14Q33410348-C82124CF-119A-4711-8366-0E34E9B9FE62Q33410572-E068FF7F-BA6D-4F6F-80CA-0FB149C49EA4Q33410653-F078BCF7-0B71-4B9E-8BBD-DC0D16558A4AQ33412584-E4B4F837-310F-4FCD-89F0-F333C3A0691AQ33416258-AC9DC58D-CCD2-4DA3-B38F-20DCB79508E1Q33416569-BEEEF45B-7A58-4392-A0C6-BC83581DB439Q33419712-C6CC29BD-5656-4688-ADA1-3BDBAD214379
P2860
Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Rituximab efficacy and safety ...... ive multicenter phase 2 study.
@ast
Rituximab efficacy and safety ...... ive multicenter phase 2 study.
@en
type
label
Rituximab efficacy and safety ...... ive multicenter phase 2 study.
@ast
Rituximab efficacy and safety ...... ive multicenter phase 2 study.
@en
prefLabel
Rituximab efficacy and safety ...... ive multicenter phase 2 study.
@ast
Rituximab efficacy and safety ...... ive multicenter phase 2 study.
@en
P2093
P1433
P1476
Rituximab efficacy and safety ...... ive multicenter phase 2 study.
@en
P2093
Anne Vekhoff
Bruno Varet
Emmanuelle Bourgeois
François Lefrère
Jerôme Stirnemann
Lionel Galicier
Marc Michel
Marie-Paule Chauveheid
Mehdi Khellaf
Michel Leporrier
P304
P356
10.1182/BLOOD-2008-01-131029
P407
P577
2008-05-07T00:00:00Z